Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Trial Profile

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Preliminary results pooled from four neoadjuvant therapy clinical trials (NCT02437279, NCT02231775, NCT02519322, NCT01972347; n=58), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 03 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top